This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Morrell, J. Search for Related Content Social Bookmarking                         What's this?

Initiating antiplatelet therapy in diabetes: a PCO view

Department of Cardiology, Conquest Hospital, The Ridge, St. Leonards-on-Sea, East Sussex, TN37 7RD, UK, drjmmorrell{at}aol.com

Antiplatelet therapy has a role in the primary and secondary prevention of serious vascular events, especially in high-risk patients, including people with diabetes. This review considers the evidence and guideline recommendations for initiating antiplatelet therapy in people with diabetes with and without vascular disease. It concludes that, for diabetic patients with coronary heart disease, stroke or peripheral vascular disease, an antiplatelet agent (e.g. aspirin 75 mg per day or clopidogrel 75 mg per day) should be given routinely and continued in the long term. For diabetic patients with acute coronary syndromes, the addition of clopidogrel (75 mg daily) to usual therapy should be considered. For primary prevention, aspirin (75 mg) should be considered for all diabetic patients with well controlled hypertension and a 20% risk of developing coronary disease over 10 years.

Key Words: diabetes • platelets • vascular disease • aspirin • clopidogrel.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 349-353 (2003)
DOI: 10.1177/14746514030030050701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?